Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salicornia europaea L. ethyl acetate fraction
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SE-ETAC is an ethyl acetate fraction derived from *Salicornia europaea* L., a halophytic coastal herb commonly known as glasswort. It is being investigated as a natural therapeutic intervention for obesity and associated metabolic disorders. SE-ETAC exerts its effects primarily by upregulating the Heme oxygenase-1 (HO-1)/Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and activating AMP-activated protein kinase (AMPK) signaling. These molecular actions lead to the inhibition of adipogenesis, enhancement of lipolysis, and the induction of adipose browning—the conversion of white adipocytes into metabolically active beige cells—through the upregulation of thermogenic markers such as UCP1, PRDM16, and PGC-1α. Furthermore, SE-ETAC demonstrates anti-inflammatory and antioxidant properties by reducing reactive oxygen species (ROS) and suppressing proinflammatory cytokines including IL-6, IL-1β, and TNF-α.
- Other names
- Salicornia europaea ethyl acetate extractSE ethyl acetate fraction
02
Targets
HMOX1 (Heme oxygenase 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on Salicornia europaea L. ethyl acetate fraction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salicornia europaea L. ethyl acetate fraction.